Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of neuroinflammation, neurodegeneration, pain, cancer, diarrhea, inflammatory bowel disease, irritable bowel syndrome and psychiatric disorders.